Inhibition of mTOR promotes hyperthermia sensitivity in SMMC-7721 human hepatocellular carcinoma cell line

Wang,Qing‑Liang; Liu,Bo; Li,Xiao‑Jie; Hu,Kun‑Peng; Zhao,Kun; Ye,Xiao‑Ming

doi:10.3892/etm.2016.2979

Inhibition of mTOR promotes hyperthermia sensitivity in SMMC-7721 human hepatocellular carcinoma cell line

Authors:
- Qing‑Liang Wang
- Bo Liu
- Xiao‑Jie Li
- Kun‑Peng Hu
- Kun Zhao
- Xiao‑Ming Ye
View Affiliations

Affiliations: Department of General Surgery, Ling Nan Hospital, The Third Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510530, P.R. China, Department of Laboratory Medicine, Ling Nan Hospital, The Third Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510530, P.R. China
Published online on: January 11, 2016 https://doi.org/10.3892/etm.2016.2979
Pages: 961-968

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mammalian target of rapamycin (mTOR) is a critical mediator of the phosphoinositide 3‑kinase/protein kinase B/mTOR signaling pathway, and mTOR activity is induced following heat shock. Thermotherapy is used to treat hepatocellular carcinoma (HCC). However, the role of mTOR in modulating thermosensitivity in HCC has yet to be elucidated. In the present study, the antisense plasmid pEGFP‑C1‑mTOR was transfected into SMMC‑7721 cells, and the expression levels of mTOR were analyzed by reverse transcription‑polymerase chain reaction and western blot analysis. The thermal responses of the transfected cells were also examined. The results revealed that SMMC‑7721 cells were sensitive to heat treatment, and cell viability was significantly inhibited following hyperthermia treatment (P<0.01). The mRNA and protein expression levels of mTOR decreased post‑transfection. Cell proliferation, colony‑forming ability and motility were all significantly decreased following hyperthermia treatment in the transfected cells. Flow cytometry analysis demonstrated that apoptosis was significantly increased following treatment (P<0.01). The number of cells in S phase was increased, and the cell cycle was arrested in S phase. In conclusion, inhibition of mTOR increased the thermosensitivity of SMMC‑7721 cells by increasing cellular apoptosis and inducing S phase arrest.

View Figures

View References

1	Waly RS, Yangde Z and Yuxiang C: Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol. 2012:4216732012.PubMed/NCBI
2	Yang JD and Roberts LR: Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 24:899–919. 2010. View Article : Google Scholar : PubMed/NCBI
3	Roti Roti JL: Cellular responses to hyperthermia (40-46 degrees C): Cell killing and molecular events. Int J Hyperthermia. 24:3–15. 2008. View Article : Google Scholar : PubMed/NCBI
4	Habash RW, Bansal R, Krewski D and Alhafid HT: Thermal therapy, part. 2 hyperthermia techniques. Crit Rev Biomed Eng. 34:491–542. 2006. View Article : Google Scholar : PubMed/NCBI
5	Mayrhauser U, Stiegler P, Stadlbauer V, Koestenbauer S, Leber B, Konrad K, Iberer F, Portugaller RH and Tscheliessnigg K: Effect of hyperthermia on liver cell lines: Important findings for thermal therapy in hepatocellular carcinoma. Anticancer Res. 31:1583–1588. 2011.PubMed/NCBI
6	Ahmed K and Zaidi SF: Treating cancer with heat: Hyperthermia as promising strategy to enhance apoptosis. J Pak Med Assoc. 63:504–508. 2013.PubMed/NCBI
7	Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ and van Gulik TM: Outcome of regional and local ablative therapies for hepatocellular carcinoma: A collective review. Eur J Surg Oncol. 31:331–347. 2005. View Article : Google Scholar : PubMed/NCBI
8	Decadt B and Siriwardena AK: Radiofrequency ablation of liver tumours: systematic review. Lancet Oncol. 5:550–560. 2004. View Article : Google Scholar : PubMed/NCBI
9	Griffin RJ, Dings RP, Jamshidi-Parsian A and Song CW: Mild temperature hyperthermia and radiation therapy: Role of tumour vascular thermotolerance and relevant physiological factors. Int J Hyperthermia. 26:256–263. 2010. View Article : Google Scholar : PubMed/NCBI
10	Sonna LA, Fujita J, Gaffin SL and Lilly CM: Invited review: Effects of heat and cold stress on mammalian gene expression. J Appl Physiol (1985). 92:1725–1742. 2002. View Article : Google Scholar : PubMed/NCBI
11	Deng H, Ravikumar TS and Yang WL: Bone morphogenetic protein-4 inhibits heat-induced apoptosis by modulating MAPK pathways in human colon cancer HCT116 cells. Cancer Lett. 256:207–217. 2007. View Article : Google Scholar : PubMed/NCBI
12	Ma N, Szmitko P, Brade A, Chu I, Lo A, Woodgett J, Klamut H and Liu FF: Kinase-dead PKB gene therapy combined with hyperthermia for human breast cancer. Cancer Gene Ther. 11:52–60. 2004. View Article : Google Scholar : PubMed/NCBI
13	Buitrago-Molina LE and Vogel A: mTor as a potential target for the prevention and treatment of hepatocellular carcinoma. Curr Cancer Drug Targets. 12:1045–1061. 2012. View Article : Google Scholar : PubMed/NCBI
14	Shaw M, Cohen P and Alessi DR: The activation of protein kinase B by H2O2 or heat shock is mediated by phosphoinositide 3-kinase and not by mitogen-activated protein kinase-activated protein kinase-2. Biochem J. 336(Pt 1): 241–246. 1998. View Article : Google Scholar : PubMed/NCBI
15	Soares PI, Ferreira IM, Igreja RA, Novo CM and Borges JP: Application of hyperthermia for cancer treatment: recent patents review. Recent Pat Anticancer Drug Discov. 7:64–73. 2012. View Article : Google Scholar : PubMed/NCBI
16	Kouloulias V, Plataniotis G, Kouvaris J, Dardoufas C, Gennatas C, Uzunoglu N, Papavasiliou C and Vlahos L: Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: Feasibility and long-term results from a phase II randomized trial. Am J Clin Oncol. 28:91–99. 2005. View Article : Google Scholar : PubMed/NCBI
17	Palazzi M, Maluta S, Dall'Oglio S and Romano M: The role of hyperthermia in the battle against cancer. Tumori. 96:902–910. 2010.PubMed/NCBI
18	Armour EP, McEachern D, Wang Z, Corry PM and Martinez A: Sensitivity of human cells to mild hyperthermia. Cancer Res. 53:2740–2744. 1993.PubMed/NCBI
19	Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R and Riess H: The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 43:33–56. 2002. View Article : Google Scholar : PubMed/NCBI
20	Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, Felix R and Schlag PM: Hyperthermia in combined treatment of cancer. Lancet Oncol. 3:487–497. 2002. View Article : Google Scholar : PubMed/NCBI
21	Gourgou E, Aggeli IK, Beis I and Gaitanaki C: Hyperthermia-induced Hsp70 and MT20 transcriptional upregulation are mediated by p38-MAPK and JNKs in Mytilus galloprovincialis (Lamarck); a pro-survival response. J Exp Biol. 213:347–357. 2010. View Article : Google Scholar : PubMed/NCBI
22	Georgakis GV and Younes A: From Rapa Nui to rapamycin: Targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev Anticancer Ther. 6:131–140. 2006. View Article : Google Scholar : PubMed/NCBI
23	Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, Travis R, Sausville EA and Houghton PJ: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res. 7:1758–1764. 2001.PubMed/NCBI
24	Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL and Reddy SA: The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun. 331:295–302. 2005. View Article : Google Scholar : PubMed/NCBI
25	Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, et al: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 22:909–918. 2004. View Article : Google Scholar : PubMed/NCBI
26	Parent R, Kolippakkam D, Booth G and Beretta L: Mammalian target of rapamycin activation impairs hepatocytic differentiation and targets genes moderating lipid homeostasis and hepatocellular growth. Cancer Res. 67:4337–4345. 2007. View Article : Google Scholar : PubMed/NCBI
27	Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR, Schmid KW and Baba HA: Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 48:83–90. 2008. View Article : Google Scholar : PubMed/NCBI
28	Guo Y, Liang X, Lu M, Weng T, Liu Y and Ye X: Mammalian target of rapamycin as a novel target in the treatment of hepatocellular carcinoma. Hepatogastroenterology. 57:913–918. 2010.PubMed/NCBI
29	Hui IC, Tung EK, Sze KM, Ching YP and Ng IO: Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma. Liver Int. 30:65–75. 2010. View Article : Google Scholar : PubMed/NCBI
30	Ma N, Jin J, Lu F, Woodgett J and Liu FF: The role of protein kinase B (PKB) in modulating heat sensitivity in a human breast cancer cell line. Int J Radiat Oncol Biol Phys. 50:1041–1050. 2001. View Article : Google Scholar : PubMed/NCBI
31	Ohnishi K, Yasumoto J, Takahashi A and Ohnishi T: LY294002, an inhibitor of PI-3 K, enhances heat sensitivity independently of p53 status in human lung cancer cells. Int J Oncol. 29:249–253. 2006.PubMed/NCBI
32	Chin YR and Toker A: Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal. 21:470–476. 2009. View Article : Google Scholar : PubMed/NCBI
33	Zölzer F and Streffer C: Quiescence in S-phase and G1 arrest induced by irradiation and/or hyperthermia in six human tumour cell lines of different p53 status. Int J Radiat Biol. 76:717–725. 2000. View Article : Google Scholar : PubMed/NCBI
34	Ekim B, Magnuson B, Acosta-Jaquez HA, Keller JA, Feener EP and Fingar DC: mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression. Mol Cell Biol. 31:2787–2801. 2011. View Article : Google Scholar : PubMed/NCBI
35	Masuda M, Shimomura M, Kobayashi K, Kojima S and Nakatsura T: Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines. Oncol Rep. 26:1273–1279. 2011.PubMed/NCBI